{"classes":[{"categories":[{"measurements":[{"comment":"Median OS and CI are not able to be estimated due to a low number of deaths","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The overall survival (OS) is defined as the time from registration to death due to any cause. The distribution of OS will be estimated using method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15 and daratumumab IV on days 1 and 2 of cycle 1 then days 8, 15, and 22 of cycle 1, then, days 1, 8, 15, and 22 of cycle 2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8 15, and 22, and selinexor PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\\>\n\n\\> Carfilzomib: Given IV\\>\n\n\\> Daratumumab: Given IV\\>\n\n\\> Dexamethasone: Given PO\\>\n\n\\> Quality-of-Life Assessment: Ancillary studies\\>\n\n\\> Selinexor: Given PO","id":"OG000","title":"Treatment (Carfilzomib, Daratumumab, Dexamethasone, Selinexor)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}